Shenzhen Kangtai Biological Products (SHE:300601) launched the phase III clinical trials of the adsorbed acellular pertussis, diphtheria, and tetanus (component) combined vaccine, according to a Shenzhen bourse filing on May 30.
The vaccine is intended to prevent pertussis, diphtheria, and tetanus in infants and young children aged 2 months and older.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.